

August 5, 2020

To,  
**SINGAPORE EXCHANGE SECURITIES  
TRADING LIMITED**  
11 North Buona Vista Drive,  
#06-07 The Metropolis Tower 2,  
Singapore – 138589

Dear Sirs,

**Sub:- Board Meeting**

We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, August 14, 2020, inter alia, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2020.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2020 to August 16, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First Quarter ended June 30, 2020.

The above is for your information.

Thanking you.

Yours faithfully,

**For Glenmark Pharmaceuticals Limited**

HARISH  
VINAYAK KUBER

Digitally signed by  
HARISH VINAYAK KUBER  
Date: 2020.08.05 18:15:08  
+05'30'

**Harish Kuber**  
**Company Secretary Compliance Officer**

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)